These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2451526)

  • 1. Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells.
    Sobrero AF; McGuire JJ; Bertino JR
    Biochem Pharmacol; 1988 Mar; 37(6):997-1001. PubMed ID: 2451526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase.
    Fernandes DJ; Cardenas RM; Bertino JR; Hynes JB
    Adv Exp Med Biol; 1983; 163():341-57. PubMed ID: 6688493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells.
    McGuire JJ; Sobrero AF; Hynes JB; Bertino JR
    Cancer Res; 1987 Nov; 47(22):5975-81. PubMed ID: 3664501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.
    Gibson W; Bisset GM; Marsham PR; Kelland LR; Judson IR; Jackman AL
    Biochem Pharmacol; 1993 Feb; 45(4):863-9. PubMed ID: 7680860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
    Hanlon MH; Ferone R
    Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
    Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 5,8-dideazaisofolic acid (IAHQ) on human tumor cells in culture and on normal and tumor-bearing hamsters.
    Tsang KY; Hynes JB; Fudenberg HH
    Chemotherapy; 1982; 28(4):276-82. PubMed ID: 6956488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the mechanism of antitumor action of 2-desamino-2-methyl-5,8-dideazaisofolic acid.
    Hagan RL; Duch DS; Smith GK; Hanlon MH; Shane B; Freisheim JH; Hynes JB
    Biochem Pharmacol; 1991 Mar; 41(5):781-7. PubMed ID: 1998533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved synthesis and antitumor evaluation of 5,8-dideazaisofolic acid and closely related analogues.
    Hynes JB; Yang YC; McGill JE; Harmon SJ; Washtien WL
    J Med Chem; 1984 Feb; 27(2):232-5. PubMed ID: 6694171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.
    Jackson RC; Jackman AL; Calvert AH
    Biochem Pharmacol; 1983 Dec; 32(24):3783-90. PubMed ID: 6661252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
    Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
    Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
    Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
    Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
    Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
    Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.